Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
Saved in:
| Title: | Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. |
|---|---|
| Authors: | Gabe MBN; Novo Nordisk A/S, Søborg, Denmark., Fuhr R; Parexel International GmbH, Berlin, Germany., Sinn A; Parexel International GmbH, Berlin, Germany., Eliasen A; Novo Nordisk A/S, Søborg, Denmark., Berthelsen KK; Novo Nordisk A/S, Søborg, Denmark., Kuhlman AB; Novo Nordisk A/S, Søborg, Denmark., Bækdal TA; Novo Nordisk A/S, Søborg, Denmark., Nejad AB; Novo Nordisk A/S, Søborg, Denmark. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Dec; Vol. 26 (12), pp. 5805-5811. Date of Electronic Publication: 2024 Sep 16. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.15951 |
